FLURBIPROFEN SODIUM

Post-LOE

flurbiprofen sodium

Bausch + Lomb

ANDAOPHTHALMICSOLUTION/DROPS

Approved

Jan 1995

Lifecycle

Post-LOE

Competitive Pressure

30/100

Data completeness

3/8 — Basic

FLURBIPROFEN SODIUM (flurbiprofen sodium) by Bausch + Lomb is clinical pharmacology flurbiprofen sodium is one of a series of phenylalkanoic acids that have shown analgesic, antipyretic, and anti-inflammatory activity in animal inflammatory diseases. First approved in 1995.

Drug data last refreshed 21h ago

$0.0BPart D

Mechanism of Action

CLINICAL PHARMACOLOGY Flurbiprofen sodium is one of a series of phenylalkanoic acids that have shown analgesic, antipyretic, and anti-inflammatory activity in animal inflammatory diseases. Its mechanism of action is believed to be through inhibition of the cyclo-oxygenase enzyme that is essential…

Indications

Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.

Company

Worked on FLURBIPROFEN SODIUM at Bausch + Lomb? Share your interview experience or compensation data (+7 days Pro)

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.